Skip to content

Zepbound side effects: what the label reports

By the glp1doses editorial team
Every number is checked against FDA labels and official price pages. How we check

The short answer

The most common Zepbound side effects in the label's trials were nausea (25% to 29% across the three doses, 8% on placebo), diarrhea (19% to 23%), constipation (11% to 17%) and vomiting (8% to 13%). Those figures come from two pooled trials in 2,519 adults with obesity or overweight, treated for up to 72 weeks. Call your prescriber if nausea, vomiting or diarrhea leaves you dehydrated.

Source: Zepbound FDA label

Key takeaways

  • Nausea, diarrhea, constipation and vomiting lead the Zepbound table. Most nausea, vomiting and diarrhea came while the dose was being raised.
  • Zepbound carries a boxed warning, the strongest kind the FDA requires, about thyroid C-cell tumors.
  • It must not be used with a personal or family history of medullary thyroid carcinoma or with MEN 2.
  • Call your prescriber about severe abdominal pain or dehydration. A serious allergic reaction needs urgent medical care.
  • Don't change or skip a dose on your own because of a side effect.

How often it was reported in the label's trials

Zepbound: Table 1: Adverse Reactions (≥2% and Greater than Placebo) in ZEPBOUND-Treated Adults with Obesity or Overweight in Weight Reduction and Long-term Maintenance Trials (Study 1 and Study 2) · Pool of two randomized, double-blind, placebo-controlled weight reduction trials (Study 1 and Study 2) that included 2,519 adults with obesity or overweight, with or without type 2 diabetes, treated with Zepbound for up to 72 weeks plus a 4-week off-drug follow-up period.
ReactionPlacebon=9585 mgn=63010 mgn=94815 mgn=941
Nausea8%25%29%28%
Diarrhea8%19%21%23%
Vomiting2%8%11%13%
Constipation5%17%14%11%
Abdominal Pain5%9%9%10%
Dyspepsia4%9%9%10%
Injection Site Reactions2%6%8%8%
Fatigue3%5%6%7%
Hypersensitivity Reactions3%5%5%5%
Eructation1%4%5%5%
Hair Loss1%5%4%5%
Gastroesophageal Reflux Disease2%4%4%5%
Flatulence2%3%3%4%
Abdominal Distension2%3%3%4%
Dizziness2%4%5%4%
Hypotension0%1%1%2%

Zepbound: Gastrointestinal adverse reactions

In a pool of Study 1 and 2, gastrointestinal adverse reactions occurred more frequently among patients receiving ZEPBOUND (5 mg 56%, 10 mg 56%, 15 mg 56%) than placebo (30%). More patients receiving ZEPBOUND 5 mg (1.9%), ZEPBOUND 10 mg (3.3%), and ZEPBOUND 15 mg (4.3%) discontinued treatment due to gastrointestinal adverse reactions than patients receiving placebo (0.5%). The majority of nausea, vomiting, and/or diarrhea events occurred during dose escalation and decreased over time.

Zepbound: Hair loss

Hair loss adverse reactions in ZEPBOUND-treated patients were associated with weight reduction. In a pool of Study 1 and 2, hair loss was reported more frequently in female than male patients in the ZEPBOUND (7.1% female versus 0.5% male) and placebo (1.3% female versus 0% male) treatment groups. No ZEPBOUND-treated patients and one placebo-treated patient discontinued study treatment due to hair loss.

Zepbound: Injection site reactions

In ZEPBOUND-treated patients in a pool of Study 1 and 2, injection site reactions were more frequent in those with anti-tirzepatide antibodies (11.3%) compared to those who did not develop anti-tirzepatide antibodies (1%) [see Clinical Pharmacology (12.6)].

Zepbound: Hypersensitivity reactions

In a pool of Study 1 and 2, immediate hypersensitivity reactions (within one day after drug administration) occurred in 2.1% of ZEPBOUND-treated patients compared to 0.4% of placebo-treated patients, while non-immediate hypersensitivity reactions occurred in 3.5% of ZEPBOUND-treated patients compared to 2.7% of placebo-treated patients.

Zepbound: Acute gallbladder disease

In a pool of Study 1 and 2, cholelithiasis was reported in 1.1% of ZEPBOUND-treated patients and 1% of placebo-treated patients, cholecystitis was reported in 0.7% of ZEPBOUND-treated patients and 0.2% of placebo-treated patients, and cholecystectomy was reported in 0.2% of ZEPBOUND-treated patients and no placebo-treated patients.

Zepbound: Hypoglycemia

In Study 2, a trial of patients with type 2 diabetes mellitus and BMI ≥27 kg/m², hypoglycemia (plasma glucose <54 mg/dL) was reported in 4.2% of ZEPBOUND-treated patients versus 1.3% of placebo-treated patients.

Zepbound: Hypoglycemia in adults without type 2 diabetes

In Study 1, a trial of ZEPBOUND in adults with obesity/overweight without type 2 diabetes mellitus, there was no systematic capturing of hypoglycemia, but plasma glucose <54 mg/dL was reported in 0.3% of ZEPBOUND-treated patients versus no placebo-treated patients.

Zepbound: Heart rate increase

In a pool of Study 1 and 2, treatment with ZEPBOUND resulted in a mean increase in heart rate of 1 to 3 beats per minute compared to no increase in placebo-treated patients.

Zepbound: Hypotension

In a pool of Study 1 and 2, hypotension occurred more frequently among patients taking ZEPBOUND (1.6%) than patients taking placebo (0.1%). Hypotension was more frequently seen in ZEPBOUND-treated patients on concomitant antihypertensive therapy (2.2%) compared to ZEPBOUND-treated patients not on antihypertensive therapy (1.2%).

Zepbound: Dysesthesia

In a pool of Study 1 and 2, dysesthesia occurred more frequently among patients receiving ZEPBOUND (5 mg 0.2%, 10 mg 0.2%, 15 mg 0.4%) than placebo (0.1%).

Zepbound: Dysgeusia

In a pool of Study 1 and 2, dysgeusia was reported by 0.4% of ZEPBOUND-treated patients and no placebo-treated patients.

Zepbound: Dry mouth

In a pool of Study 1 and 2, dry mouth or dry throat was reported by 1% of ZEPBOUND-treated patients and 0.1% of placebo-treated patients.

Zepbound: Acute kidney injury

In a pool of Study 1 and 2, acute kidney injury was reported in 0.5% of ZEPBOUND-treated patients compared to 0.2% of placebo-treated patients.

Zepbound: Acute pancreatitis

In a pool of two ZEPBOUND clinical trials for weight reduction (Studies 1 and 2), 0.2% of ZEPBOUND-treated patients had acute pancreatitis confirmed by adjudication (0.14 patients per 100 years of exposure) versus 0.2% of placebo-treated patients (0.15 patients per 100 years of exposure).

Zepbound: Amylase and lipase increase

In a pool of Study 1 and 2, treatment with ZEPBOUND resulted in mean increases from baseline in serum pancreatic amylase concentrations of 20% to 25% and serum lipase concentrations of 28% to 35%, compared to mean increases from baseline in pancreatic amylase of 2.1% and serum lipase of 5.8% in placebo-treated patients.

FDA label: Zepbound, Revised: 8/2026 (DailyMed version 40)

Warnings on the Zepbound label

  • Risk of Thyroid C-Cell Tumors

    Tirzepatide caused thyroid C-cell tumors in rats, and it is not known whether Zepbound causes them in people.

    In rats, tirzepatide caused a dose-dependent and treatment-duration-dependent increase in the incidence of thyroid C-cell tumors (adenomas and carcinomas) in a 2-year study at clinically relevant plasma exposures [see Nonclinical Toxicology (13.1)]. It is unknown whether ZEPBOUND causes thyroid C-cell tumors, including MTC, in humans as human relevance of tirzepatide-induced rodent thyroid C-cell tumors has not been determined.
  • Severe Gastrointestinal Adverse Reactions

    Zepbound can cause stomach and bowel side effects that are sometimes severe, and it is not recommended for people with severe gastroparesis.

    Use of ZEPBOUND has been associated with gastrointestinal adverse reactions, sometimes severe [see Adverse Reactions (6)]. In a pool of two ZEPBOUND clinical trials for weight reduction (Studies 1 and 2), severe gastrointestinal adverse reactions were reported more frequently among patients receiving ZEPBOUND (5 mg 1.7%, 10 mg 2.5%, 15 mg 3.1%) than placebo (1%).
  • Acute Kidney Injury Due to Volume Depletion

    Dehydration from nausea, vomiting or diarrhea has led to acute kidney injury in some patients.

    There have been postmarketing reports of acute kidney injury, in some cases requiring hemodialysis, in patients treated with GLP-1 receptor agonists, or ZEPBOUND [see Adverse Reactions (6.2)]. The majority of the reported events occurred in patients who experienced gastrointestinal adverse reactions leading to dehydration such as nausea, vomiting, or diarrhea [see Adverse Reactions (6.1)].
  • Acute Gallbladder Disease

    Zepbound is associated with more gallbladder problems such as gallstones and gallbladder inflammation.

    Treatment with ZEPBOUND and GLP-1 receptor agonists is associated with an increased occurrence of acute gallbladder disease.
  • Acute Pancreatitis

    Inflammation of the pancreas, including fatal cases, has been observed, and Zepbound should be stopped if pancreatitis is suspected.

    Acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with GLP-1 receptor agonists, or ZEPBOUND [see Adverse Reactions (6)].
  • Hypersensitivity Reactions

    Serious allergic reactions such as anaphylaxis and angioedema have been reported with tirzepatide.

    There have been postmarketing reports of serious hypersensitivity reactions (e.g., anaphylaxis, angioedema) in patients treated with tirzepatide. In a pool of two ZEPBOUND clinical studies for weight reduction (Studies 1 and 2), 0.1% of ZEPBOUND-treated patients had severe hypersensitivity reactions compared to no placebo-treated patients.
  • Hypoglycemia

    Zepbound lowers blood sugar and can cause low blood sugar, with higher risk when used with insulin or a sulfonylurea.

    ZEPBOUND lowers blood glucose and can cause hypoglycemia.
  • Diabetic Retinopathy Complications in Patients with Type 2 Diabetes Mellitus

    Rapid improvement in blood sugar has been linked to temporary worsening of diabetic retinopathy, so patients with a history of it should be monitored.

    Temporary worsening of diabetic retinopathy has been reported with rapid improvement in glucose control. Patients with a history of diabetic retinopathy should be monitored for progression of diabetic retinopathy.
  • Pulmonary Aspiration During General Anesthesia or Deep Sedation

    Because Zepbound slows stomach emptying, there have been rare reports with GLP-1 medicines of stomach contents entering the lungs during anesthesia or deep sedation.

    ZEPBOUND delays gastric emptying [see Clinical Pharmacology (12.2)]. There have been rare postmarketing reports of pulmonary aspiration in patients receiving GLP-1 receptor agonists undergoing elective surgeries or procedures requiring general anesthesia or deep sedation who had residual gastric contents despite reported adherence to preoperative fasting recommendations.
  • Never Share a ZEPBOUND KwikPen Between Patients

    A Zepbound KwikPen must never be shared between patients, even with a new needle, because of infection risk.

    Never share ZEPBOUND KwikPen between patients, even if the pen needle is changed. Sharing poses a risk for transmission of blood-borne pathogens.

If a side effect has you worried, call your prescriber about nausea, vomiting or diarrhea that leaves you dehydrated, and about severe abdominal pain. Signs of a serious allergic reaction need urgent medical care. Don’t change or skip a dose on your own.

Zepbound’s label takes its side-effect figures from a pool of two placebo-controlled weight reduction trials (Study 1 and Study 2). They included 2,519 adults with obesity or overweight, with or without type 2 diabetes, treated for up to 72 weeks. A placebo group gets an inactive treatment instead of the medicine.

What are the most common side effects of Zepbound?

Stomach and bowel reactions lead the table. Each line gives the share of patients who reported the reaction at 5 mg, 10 mg and 15 mg, then the placebo group.

Two things stand out. The placebo column is never zero: 8% of people who got no tirzepatide also reported nausea. And a higher dose didn’t always mean a higher rate. Constipation was most frequent at 5 mg, and nausea peaked at 10 mg.

How common are stomach side effects on Zepbound?

Counted together, gastrointestinal (stomach and bowel) reactions were reported by 56% of patients at each of the three doses, against 30% on placebo. The label says the majority of nausea, vomiting and diarrhea events “occurred during dose escalation and decreased over time.” Dose escalation is the weeks when the dose is being raised.

Severe gastrointestinal reactions were much less common: 1.7% at 5 mg, 2.5% at 10 mg and 3.1% at 15 mg, against 1% on placebo. The label says Zepbound is not recommended in patients with severe gastroparesis (a stomach that empties very slowly).

Does Zepbound cause hair loss, dizziness or low blood pressure?

Hair loss was reported by 5%, 4% and 5% of patients across the three doses, against 1% on placebo. Women reported it far more often than men: 7.1% against 0.5% on Zepbound. The label says these reactions “were associated with weight reduction.” See hair loss.

Dizziness was reported by 4% to 5% of Zepbound patients and 2% on placebo.

Low blood pressure was reported by 1.6% of Zepbound patients and 0.1% on placebo. It was more frequent in patients also taking blood pressure medicine (2.2%) than in those who were not (1.2%).

What is the boxed warning, and what are the serious side effects?

Zepbound carries a boxed warning for thyroid C-cell tumors. A boxed warning is the strongest kind the FDA requires, set apart in a box on the label. Tirzepatide causes these tumors in rats. In the label’s words, “It is unknown whether ZEPBOUND causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans.” Zepbound is contraindicated, meaning it must not be used, in patients with a personal or family history of MTC or with MEN 2 (Multiple Endocrine Neoplasia syndrome type 2).

The other warnings, with the trial figures the label gives:

  • Acute kidney injury: 0.5% on Zepbound and 0.2% on placebo. Postmarketing reports (made after approval), some requiring hemodialysis (a machine filters the blood), mostly involved patients dehydrated by nausea, vomiting or diarrhea.
  • Gallbladder disease: gallstones in 1.1% on Zepbound and 1% on placebo, gallbladder inflammation in 0.7% and 0.2%.
  • Acute pancreatitis (inflammation of the pancreas): confirmed in 0.2% of patients in both groups. Fatal cases have been observed with this class of medicines.
  • Serious allergic reactions: anaphylaxis, a sudden and severe whole-body reaction, and angioedema, swelling under the skin, have been reported. Severe hypersensitivity (allergic) reactions occurred in 0.1% of Zepbound patients in the trials.
  • Low blood sugar: in the trial of patients with type 2 diabetes, glucose below 54 mg/dL was reported in 4.2% on Zepbound and 1.3% on placebo. The risk is higher with insulin or a sulfonylurea, a type of diabetes pill.
  • Diabetic retinopathy (eye damage from diabetes), pulmonary aspiration (stomach contents entering the lungs) during general anesthesia or deep sedation, and a warning never to share a Zepbound KwikPen.

The safety guide covers these warnings across all the medicines.

How many people stop Zepbound because of side effects?

Across both trials, 4.8% of patients on 5 mg, 6.3% on 10 mg and 6.7% on 15 mg permanently stopped treatment because of side effects, compared with 3.4% on placebo. Gastrointestinal reactions alone accounted for 1.9%, 3.3% and 4.3%, against 0.5% on placebo. The label adds that most of these patients stopped “during the first few months of treatment.”

When to call your prescriber

The label is written for clinicians, and its warnings show what they need to hear from you:

  • Nausea, vomiting or diarrhea that leaves you dehydrated, because of the kidney injury reports.
  • Severe abdominal pain. The label says Zepbound should be stopped if pancreatitis is suspected.
  • Signs of a serious allergic reaction, which needs urgent medical care.
  • A planned surgery or procedure with general anesthesia or deep sedation, since Zepbound delays stomach emptying.
  • A history of diabetic retinopathy, which the label says should be monitored.

Don’t change or skip a dose on your own because of a side effect. That decision belongs to your prescriber. For everything else about this medicine, start at the Zepbound guide, or see the side effects guide for each reaction across all eight labels.

Frequently asked questions

What are the most common side effects of Zepbound?

Nausea, diarrhea, vomiting and constipation. In the label's two pooled trials, 25% of patients at 5 mg, 29% at 10 mg and 28% at 15 mg reported nausea, against 8% on placebo. Diarrhea was reported by 19%, 21% and 23%, vomiting by 8%, 11% and 13%, and constipation by 17%, 14% and 11%.

How long do Zepbound side effects last?

The label says most nausea, vomiting and diarrhea events occurred during dose escalation (while the dose was being raised) and decreased over time. It also says most patients who stopped Zepbound because of side effects did so during the first few months of treatment. Both statements describe the whole trial group, not what you personally should expect.

Does Zepbound cause hair loss?

Hair loss is in the label's table: 5% of patients at 5 mg, 4% at 10 mg and 5% at 15 mg, against 1% on placebo. Women reported it more often (7.1%) than men (0.5%). The label says hair loss was associated with weight reduction, and no Zepbound patient stopped treatment because of it.

Is Zepbound safe?

The label doesn't answer with a yes or a no. It carries a boxed warning, the strongest kind the FDA requires: tirzepatide causes thyroid C-cell tumors in rats, and it's unknown whether Zepbound causes them in humans. Zepbound must not be used by people with a personal or family history of medullary thyroid carcinoma or with MEN 2. Whether it suits you is a decision for your prescriber.

What are the serious side effects of Zepbound?

The label's warnings cover severe stomach and bowel reactions, acute kidney injury after dehydration, acute gallbladder disease, acute pancreatitis, serious allergic reactions, low blood sugar, worsening of diabetic retinopathy (eye damage from diabetes) and pulmonary aspiration during anesthesia or deep sedation. In the pooled trials, severe stomach and bowel reactions were reported by 1.7% to 3.1% of Zepbound patients, against 1% on placebo.

Sources (3)

  1. 1.
    FDA label (DailyMed): Zepbound prescribing information, section 4
    “ZEPBOUND is contraindicated in patients with: A personal or family history of MTC or in patients with MEN 2 [see Warnings and Precautions (5.1)].”
  2. 2.
    FDA label (DailyMed): Zepbound prescribing information, section 5.2
    “ZEPBOUND is not recommended in patients with severe gastroparesis.”
  3. 3.